Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celtic discontinues enrollment in Xerecept trial

Celtic ( Hamilton, Bermuda) discontinued enrollment in the double-blind Phase III NTI 0302 trial,

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE